NEW YORK (TheStreet) -- Dyax Corp (DYAX) shares are jumping, up 25% to $8.25, on Tuesday after rival Biocryst (BCRX) - Get Report reported positive findings in the clinical trial for its hereditary angioedema (HAE) drug BCX416.

Investors have reacted positively to the news as it bodes well for Dyax's alternative HAE treatment DX-2930, which is currently being developed as a prophylactic HAE treatment.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

DYAX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.